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This paper describes a method of time-controlled seeding to separate the stages of nucleation
and growth in protein crystallization using a microfluidic device. We quantified microfluidic
seeding using a model protein, developed a strategy to produce diffraction-quality crystals of
proteins recalcitrant to traditional methods, and solved de novo the X-ray crystal structure of
Oligoendopeptidase F. Proteins are crystallized to determine their three-dimensional
structures, to understand protein function, and aid in drug design, but crystallization can be an
unpredictable and stochastic process.[1–4] Microfluidics is emerging as a tool to perform
crystallization trials faster, cheaper, in smaller volumes, and with a higher level of
control.[5–9] The two general stages of protein crystallization—crystal nucleation and crystal
growth—generally have differing optimal conditions.[10–12] Ideally, the protein forms crystal
nuclei at a supersaturation where ordered growth is possible (Figure 1a). However, for some
proteins a supersaturation gap exists, where there is no overlap between nucleation and growth
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conditions (Figure 1b). In the case of a supersaturation gap, solutions at low supersaturation
that promote the ordered growth of crystals may not induce nucleation. Conversely, solutions
at high supersaturation that promote nucleation may lead to growth of clustered crystals or
microcrystals. Supersaturation gaps may be bridged by decreasing concentration from high to
low supersaturation, but in traditional vapor diffusion, supersaturation increases during the
trial. Other techniques, such as free-interface diffusion,[1,8,13] decrease supersaturation during
the trial and may bridge the supersaturation gap.
Bridging the supersaturation gap by inducing nucleation has been attempted by addition of
minerals,[14] synthetically designed nucleants,[15] altering supersaturation,[1,8,13] varying
temperature,[16] and crystal seeding.[10,17,18] Seeding eliminates the need for nucleation and
growth to occur in the same solution and separates the two stages of protein crystallization in
trials that use microliter volumes and larger.[14,15,19–21] However, seeding using small (nL)
volumes can be more difficult or not possible at all, because seeds are too small to be
seen[22,23] or are too delicate to be handled.[17] To overcome these challenges, we have
developed a plug-based microfluidic system to perform seeding and bridge the supersaturation
gap in nL volumes. In this system, nucleation and growth stages of protein crystallization are
separated and controlled independently to allow the growth of single protein crystals.
The system uses soft lithography microfluidics[24] to form plugs[5] of controlled size and
composition surrounded by a fluorocarbon carrier fluid in glass microcapillaries.[25] To
separate the nucleation and growth stages, a microfluidic device was designed to control
multiple reactions in sequence and in time (Figure 2a).[26] In the nucleation stage, highly
concentrated solutions of protein and precipitants were combined to form plugs of a highly
supersaturated mixture conducive to the formation of seed crystals (functional cores/ centers
that lead to the formation of a protein crystal when added to a supersaturated crystallization
solution). Seeds must contain protein but may be too small to be seen and may be
liquid,[12,16] amorphous, or microcrystalline. The generation of seeds may take as little as a
few seconds or as long as several days, depending on the protein. By controlling flow rates and
channel length used for the nucleation stage, time control of seconds, minutes, hours, or even
days[6,26] is achievable.
To illustrate the microfluidic seeding method, seed crystals of thaumatin protein were
generated in the nucleation stage in 3–15 seconds by fixing the length of the channel and
varying the flow rates of the solutions. After 3–15 seconds, plugs containing seeds were merged
into the growth stage, where protein and precipitants were combined to form plugs at lower
supersaturation, conducive to ordered crystal growth. Plugs from the growth stage were flowed
into a glass microcapillary, where plugs were incubated and observed. When these two stages
are combined, this system displays time control[5,26] on two time scales: in seconds when
generating seeds,[26] and in hours to days when incubating plugs.[25] When growth conditions
were used alone, no crystals grew (Figure 2b). When nucleation conditions were used alone,
precipitation resulted (Figure 2c). When nucleation conditions were combined with growth
conditions under time control, single crystals grew (Figure 2d).
We used the model protein thaumatin to test the hypothesis that the number of crystals formed
can be controlled by varying the nucleation time. Tests performed at two levels of
supersaturation in the growth stage confirmed that longer nucleation times lead to more seeds
and, therefore, more crystals (Figure 3). Crystals grown without seeding were compared by X-
ray diffraction with crystals grown with seeding.[25,27,28] To ensure that no variables were
introduced by handling or cryoprotecting, crystals were analyzed inside the capillary (in situ)
by obtaining ten-frame sets of diffraction data over a 10-degree rotation range and comparing
the average signal-to-noise ratios of the detected reflections in the corresponding resolution
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shells (see the Supporting Information). Relative to the controls, crystals grew more rapidly
and in higher yield with microfluidic seeding and were of the same quality.
To validate this method with challenging structurally uncharacterized targets, we crystallized
SARS nucleocapsid N-terminal domain (“SARS protein”) and Oligoendopeptidase F from
Bacillus stearothermophilus. At high supersaturation, plugs containing solutions of “SARS
protein” consistently gave microcrystalline clusters similar to those seen in standard vapor-
diffusion methods (Figure 4, left), but no single crystals were observed. The formation of
microcrystalline clusters is consistent with either multiple independent nucleation events or
defects during growth, which are typically observed at high supersaturation.[1] At low
supersaturation, nucleation did not occur, and no crystals grew, thus suggesting a
supersaturation gap (Figure 1b). Separation of the nucleation and growth stages was achieved
in four steps (Figure 4): i) Plugs were formed under nucleation conditions. ii) The flow was
stopped to grow clusters of microcrystals over several days. iii) The clusters of microcrystals
were dispersed throughout the plug under flow. Each plug of crystals was used to seed multiple
plugs. iv) Plugs at low supersaturation (growth conditions) containing the microcrystalline
seeds were flowed into a glass capillary for incubation. This method produced single “SARS
protein” crystals (Figure 4, right). Preliminary data showed diffraction to a resolution of 3.5
Å.
As a second example, we investigated Oligoendopeptidase F, a member of the metallopeptidase
family M3 that performs proteolytic cleavage of proteins at Leu-Gly. This protein was selected
as a target by several structural genomics centers (http://sg.pdb.org). Although there has been
some success in expression, purification, and crystallization of this protein, no crystal structure
has been published. The putative protein sequence from Bacillus stearothermophilus was
selected by the Midwest Center for Structural Genomics (MCSG, http://www.mcsg.anl.gov)
in 2003, and the purified protein was kept frozen at −80°C after the first run of the crystallization
trials. In traditional vapor-diffusion trials (see the Supporting Information), clustered crystals
(Figure 5b) of Oligoendopeptidase F grew from a microcrystalline precipitation (Figure 5a)
but were unsuitable for X-ray analysis. We used microfluidics to take “seeds” from the
precipitate and flow them into “growth” crystallization solutions at lower supersaturation. The
key to the success of this approach was the very high dilution of the seeding mixture—
approximately one nL of seeds was used to seed each “growth” plug (20–100 nL). As a result
of microfluidic seeding, single needlelike crystals grew, which were used for two subsequent
rounds of seeding to wash the crystals and allow them to grow larger (Figure 5c).[18]
Microfluidic seeding significantly increased the rate of success in obtaining single crystals of
Oligoendopeptidase F suitable for X-ray analysis. Each microfluidic seeding experiment (ca.
1 μL of protein total) resulted in dozens of single crystals (ca. 50 plugs, most containing single
crystals). The crystal structure (Figure 6) of Oligoendopeptidase F was solved by the single-
wavelength anomalous diffraction (SAD) technique at a resolution of 3.3 Å by using one
crystal grown in a microfluidic capillary (see the Supporting Information). To expand the
refinement resolution to 3.1 Å (PDB code: 2H1J), we merged two data sets collected from two
different crystals grown in a microfluidic capillary.
To confirm that crystals grown by microfluidic seeding are isomorphous to ones grown by the
traditional hanging-drop vapor-diffusion method, approximately one hundred hanging-drop
vapor-diffusion trials were set up with similar crystallization conditions (ca. 100 μL of protein
total). We were fortunate that one trial—a control experiment set up during the microfluidic
trials—produced clustered crystals of suitable thickness for a piece to be extracted manually
from the cluster for X-ray analysis. The cluster was transferred to cryoprotectant, and a single
crystal was separated from the cluster by using crystal manipulation tools. The structure was
determined independently from the microfluidic crystal at a resolution of 3.0 Å (PDB code:
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2H1N). Crystals grown by both microfluidic and hanging-drop techniques are isomorphous
and belong to space group P3121 with cell dimensions a = b = 119.5 Å, c = 250 Å. The crystals
contained two protein molecules (564 amino acids, 14 Se-Met residues per molecule) in the
asymmetric unit with a solvent content of approximately 70%. Data collection, phasing, and
refinement statistics are compared in the Supporting Information.
By using time-controlled microfluidic seeding, we have separated and achieved direct control
over the nucleation and growth stages of protein crystallization. This system presents a solution
to the potential conflict between nucleation (requiring high supersaturation) and ordered
growth (requiring low supersaturation) and enables three advances that are difficult to achieve
with traditional technologies: i) control of the nucleation time with subsecond precision; ii) the
seeding of nL volumes; and iii) the use of a single plug to seed dozens of growth plugs by
injecting less than one nL of seeding solution into each growth plug. Seeding with a small part
of a single plug containing many seed crystals is important both to obtain a few single crystals
in each growth plug and to use a single sample containing microcrystalline seed crystals to
optimize growth conditions. We have not yet explored the potential of cross-seeding proteins,
as was proposed for similar proteins of different species, protein–DNA, or protein–ligand
complexes that have already been crystallized in their apo form,[1] though this work could be
valuable. We conclude that microfluidic seeding may be used to achieve crystallization of some
proteins that currently fail to crystallize and may be used to increase the success rate of future
crystallization trials.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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The nucleation and growth of protein crystals may not occur under the same conditions. a) For
some proteins, there is an overlap between the supersaturation regions for nucleation and
ordered growth, corresponding to the optimal crystallization condition. b) For other proteins,
there is a supersaturation gap between nucleation and ordered growth such that both cannot
occur at the same supersaturation.
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a) The process of microfluidic seeding. In stage 1 of the device, solutions at concentrations
that promote nucleation are combined. After a delay (t = 3–15 s, depending on the flow rate),
seed crystals formed in stage 1 are merged into stage 2 of the device, where solutions that
promote crystal growth are combined. b–d) Microphotographs of typical plugs containing
thaumatin: b) at low supersaturation (growth conditions) no nucleation occurs and no crystals
form; c) at high supersaturation (nucleation conditions) precipitation occurs; d) a single
thaumatin crystal was nucleated in stage 1 and grown in stage 2. Scale bar: 200 μm.
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Fraction (F) of plugs with crystals versus incubation time for different nucleation times
(tnuc). a) At a protein concentration of 15 mgmL−1 in the growth stage, seeded plugs yielded
crystals whereas unseeded plugs did not yield crystals. b) At a protein concentration of 25
mgmL−1 in the growth stage, seeded plugs yielded more crystals in a shorter period of time
than unseeded plugs. ♦ control 1 (no seeding), • tnuc = 9 s, ▪ tnuc = 5 s, ▴ control 2 (no seeding).
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Separating the stages of nucleation and growth in the crystallization of “SARS protein” yields
single crystals. i) Protein and precipitant solutions of high concentration are combined to form
plugs. ii) The flow is stopped, and the plugs are incubated to generate seed crystals (left
microphotograph: a typical “SARS protein” crystal grown in solutions of high supersaturation
in which excess nucleation leads to clustered microcrystals). iii) Protein and precipitant
solutions of lower concentration are combined to form plugs containing solutions at a lower
degree of supersaturation that lead to crystal growth. Each plug containing seed crystals seeds
multiple growth plugs. iv) Growth plugs that contain seed crystals are flowed into a glass
capillary and incubated (right microphotograph: two typical plugs of low supersaturation that
have been seeded with “SARS protein” microcrystals). Scale bars: 100 μm.
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Crystallization of Oligoendopeptidase F. a) Microphotograph of the precipitation that results
from a traditional vapor-diffusion trial. b) Microphotograph of a typical crystal grown at high
degree of supersaturation whereby excess nucleation led to clustered crystals. c)
Microphotograph of single crystals in a typical plug seeded by microfluidic methods. Scale
bars: 100 μm.
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Ribbon structure of Oligoendopeptidase F. The protein has neurolysin topology with a mainly
α-helical scaffold. The central groove divides the protein into two “subdomains” (shown in
cyan and red). One Zn2+ ion (shown as a small, green sphere) is bound at the active site. The
helix α13 contains the HEXXH zinc-binding motif with its two zinc-coordinating histidine
residues (His356 and His360). Additional coordination is provided by Glu384 on helix α14.
The α-helix numbering from the PDB 1O86 structure[29] was used.
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